sellWeak cluster of 5
Paul K. Audhya sold $71k of KALV
CHIEF MEDICAL OFFICER at KalVista Pharmaceuticals, Inc.. 5,296 shares at an average of $13.45, traded Nov 24, 2025, filed Nov 26, 2025.
Warning score
23Value
$71k
5,296 shares
Holdings after
131,831
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +8Trade size$71k at market
- 0Share of holdings soldSold 3.9% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001860131-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 21, 2025 | MOption exercise Common Stock | +6,250 | - | - | 132,127 | Nov 26, 2025 |
| Nov 22, 2025 | MOption exercise Common Stock | +5,000 | - | - | 137,127 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock | -5,296 | $13.45 | $71k | 131,831 | Nov 26, 2025 |
| Nov 21, 2025 | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 81,250 | Nov 26, 2025 |
| Nov 22, 2025 | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 50,000 | Nov 26, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $905k 33,800 shares | -13% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $60k 2,239 shares | -1% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $53k 1,966 shares | -1% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $40k 1,489 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $72k 2,685 shares | -2% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $293k 10,926 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $63k 2,358 shares | -1% | |
| 28Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $40k 1,489 shares | -6% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $50k 1,861 shares | -3% | |
| 20Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $28k 1,032 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.